CSL Behring KK has gained approval from Japan's Ministry of Health, Labour and Welfare (MHLW) to manufacture and market ...

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 ...

Japan's Ministry of Health, Labor and Welfare (MHLW) has granted manufacturing and marketing approval for Andembry ...

Astria advances innovative therapies for hereditary angioedema and atopic dermatitis. Strong cash position supports pivotal ...

Astria Therapeutics, Inc. , a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the ...

While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

Doctors harvest stem cells from the patient’s bone marrow and then send them off to a lab, where CRISPR is used to turn up the production of another, functional version of haemoglobin. This version is ...

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema ... but frequently do not eliminate all, angioedema attacks and require lifelong administration.

The mean monthly attack rate was 0.22 ... The EU has approved CSL's once-monthly Andembry for hereditary angioedema, challenging therapies from Takeda and Biocryst.

Twenty-seven-year-old Daniela powers a native of West Virginia. Since 20222, she has experiencing unexplained rashes and ...

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another ...